Renalytix AI
About Renalytix AI
Renalytix AI (officially Renalytix Plc since June 2021) is a pioneering healthcare AI company dedicated to developing and commercializing artificial intelligence-enabled in vitro diagnostic solutions for kidney disease. Their flagship product, KidneyIntelX, is an FDA-authorized prognostic test designed to significantly enhance the clinical management of kidney disease, with the overarching goals of improving patient outcomes and reducing healthcare costs. KidneyIntelX employs a proprietary AI-enabled algorithm that integrates diverse patient data, including validated blood-based biomarkers (such as TNFR1, TNFR2, and KIM-1), inherited genetics, and comprehensive personalized patient data extracted from electronic health record (EHR) systems. This sophisticated analysis generates a unique patient risk score, predicting the likelihood of progressive kidney function decline over a five-year period in adult patients with type 2 diabetes and chronic kidney disease (stages 1-3b).
The company’s innovative solutions empower physicians and healthcare systems to identify high-risk patients earlier than traditional methods. By providing a clear, actionable risk stratification, KidneyIntelX facilitates the implementation of targeted care plans and optimized allocation of clinical resources and medications, particularly in the early stages of CKD when interventions can be most impactful. This approach aims to transform the paradigm of kidney disease management from reactive treatment of advanced stages to proactive preservation of kidney health, thereby reducing the incidence of end-stage renal disease and the associated burden on healthcare systems. Renalytix actively collaborates with leading medical institutions, including the Mount Sinai Health System and the University of Utah, to integrate its diagnostic platform into clinical workflows, validate its efficacy, and advance research in kidney health and precision medicine.
Focus Areas
Business Intelligence
| Key Investors | Mount Sinai Health System, UBS Group AG |
| Partnerships | Tempus AI, University of Utah, America's Choice Provider Network, New York Kidney & Hypertension Medicine (NYKHM), Steno Diabetes Center, AstraZeneca |
| Acquisitions | None |
| Technology | KidneyIntelX, an AI-enabled in vitro diagnostics platform that utilizes a proprietary machine learning algorithm (random forest) to combine blood-based biomarkers (sTNFR1, sTNFR2, KIM1), inherited genetics, and electronic health record (EHR) data to generate a patient risk score for progressive kidney function decline. |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
For physicians, Renalytix AI's KidneyIntelX.dkd offers actionable, easy-to-understand risk scores (low, moderate, high) for progressive kidney function decline in patients with type 2 diabetes and early-stage CKD. This enables earlier and more appropriate intervention, allowing for targeted resource allocation and guideline-recommended treatments when they can make the most significant difference. The test helps identify patients who require more intensive care plan changes versus those who can maintain their current treatment. Furthermore, the solution is designed for seamless integration into existing clinical workflows, including one-click ordering through EHR systems, and is supported by educational resources and practical support from Renalytix.
Renalytix AI has successfully completed clinical integrations with various healthcare providers in the United States, facilitating the use of KidneyIntelX.dkd within their existing clinical workflows. Key collaborations with entities like Mount Sinai Health System and Tempus AI are instrumental in advancing EHR-integrated testing and data collection, ensuring broad access and ease of use for clinicians. Partnerships with health systems, such as the University of Utah Health, aim to embed KidneyIntelX directly into EHR systems for seamless test ordering and risk score reporting.
What the Web Says
Renalytix AI, a company focused on kidney disease diagnostics, generally receives mixed to positive reviews. Product reviews highlight the potential of their AI-driven diagnostic solutions like KidneyIntelX for early detection and risk stratification in kidney disease. Employer reviews, while less numerous, suggest a positive work environment with a focus on innovation, though some typical startup challenges might be present.
Overall: MixedStrengths
- Innovative AI-driven diagnostic solutions for kidney disease (KidneyIntelX)
- Potential for early detection and improved patient outcomes
- Strong scientific foundation and clinical validation
- Positive impact on healthcare and patient management
- Collaborative and mission-driven work environment (employer reviews)
- Focus on cutting-edge technology in healthcare
Limitations
- Relatively new company, so long-term market adoption is still developing
- Limited number of detailed product reviews on general platforms like G2/Capterra
- Specific pricing or implementation details not widely available in public reviews
- As with many startups, potential for rapid change or evolving priorities
- Reliance on healthcare system integration for widespread use
- Limited number of employer reviews for a comprehensive view
Based on reviews from: G2, Glassdoor, Capterra, Healthcare IT News, Reddit, Company press releases and investor relations (for product context)
Last updated: 2026-07-19
Videos
News, demos, and interviews about Renalytix AI.
Videos load interactively. If none appear, search YouTube for Renalytix AI →
Press & Coverage
Frequently Asked Questions
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]